Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.74 +3.9%	$23.02	$13.40 ▼ $25.88	$4.18B	0.7	1.84 million shs	3.42 million shs
AMPH Amphastar Pharmaceuticals	$30.50 +2.8%	$24.10	$20.39 ▼ $53.96	$1.38B	0.76	642,582 shs	494,895 shs
TGTX TG Therapeutics	$29.44 +2.3%	$34.09	$21.11 ▼ $46.48	$4.56B	1.95	2.89 million shs	2.18 million shs
VKTX Viking Therapeutics	$26.00 +1.3%	$31.17	$18.92 ▼ $81.73	$2.89B	0.67	8.76 million shs	10.55 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+3.87%	+1.62%	+10.61%	+17.11%	+61.58%
AMPH Amphastar Pharmaceuticals	+2.83%	+2.25%	+34.78%	+24.64%	-34.93%
TGTX TG Therapeutics	+2.33%	+4.84%	-21.70%	-14.84%	+17.43%
VKTX Viking Therapeutics	+1.33%	-35.05%	-22.16%	-3.63%	-59.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.942 of 5 stars	3.3	2.0	0.0	2.7	4.2	2.5
AMPH Amphastar Pharmaceuticals	3.3432 of 5 stars	1.3	1.0	3.7	2.9	4.2	1.3
TGTX TG Therapeutics	4.3449 of 5 stars	3.4	1.0	3.5	2.9	2.5	1.9
VKTX Viking Therapeutics	3.9993 of 5 stars	3.5	1.0	4.7	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	12.18% Upside
AMPH Amphastar Pharmaceuticals	2.50	Moderate Buy	$31.50	3.28% Upside
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	57.10% Upside
VKTX Viking Therapeutics	3.00	Buy	$86.92	234.32% Upside

Current Analyst Ratings Breakdown

Latest AMPH, VKTX, TGTX, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
8/12/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$36.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00
7/24/2025	VKTX Viking Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$125.00 ➝ $122.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.53	$0.73 per share	35.16	$4.87 per share	5.29
AMPH Amphastar Pharmaceuticals	$731.97M	1.94	$5.14 per share	5.93	$16.29 per share	1.87
TGTX TG Therapeutics	$329M	14.20	$0.12 per share	239.82	$1.74 per share	16.92
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.35	33.87	6.31	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	11.42	9.27	N/A	18.64%	20.76%	9.68%	11/5/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.37	79.57	29.44	N/A	13.31%	26.05%	9.58%	11/3/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)

Latest AMPH, VKTX, TGTX, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
TGTX TG Therapeutics	0.89	3.86	2.96
VKTX Viking Therapeutics	N/A	25.86	25.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AMPH Amphastar Pharmaceuticals	65.09%
TGTX TG Therapeutics	58.58%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
AMPH Amphastar Pharmaceuticals	27.50%
TGTX TG Therapeutics	10.64%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.71 million	Optionable
TGTX TG Therapeutics	290	158.67 million	141.78 million	Optionable
VKTX Viking Therapeutics	20	112.44 million	107.84 million	Optionable

AMPH, VKTX, TGTX, and ACAD Headlines

Recent News About These Companies

Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Price Target at $86.92

4 hours ago | americanbankingnews.com

Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?

August 22 at 4:37 PM | msn.com

Viking Therapeutics (VKTX) Reports Increased Net Losses For Second Quarter

August 22 at 4:37 PM | finance.yahoo.com

Here's Why Shares in Viking Therapeutics Crashed This Week

August 22 at 11:35 AM | msn.com

Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?

August 21 at 2:13 PM | insidermonkey.com

A Closer Look at Viking Therapeutics's Options Market Dynamics

August 21 at 1:13 PM | benzinga.com

Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?

August 21 at 1:06 PM | zacks.com

Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down - Time to Sell?

August 21 at 12:45 PM | marketbeat.com

HC Wainwright Reiterates Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

August 21 at 11:56 AM | marketbeat.com

Viking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)

August 21 at 11:17 AM | marketbeat.com

Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?

August 21 at 5:24 AM | fool.com

Steward Partners Investment Advisory LLC Acquires 13,626 Shares of Viking Therapeutics, Inc. $VKTX

August 21 at 4:43 AM | marketbeat.com

Viking Therapeutics' (VKTX) Buy Rating Reiterated at HC Wainwright

August 21 at 2:29 AM | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Buy" by Analysts

August 21 at 2:38 AM | marketbeat.com

Viking Therapeutics: Panic Creates Opportunity

August 20 at 9:02 PM | seekingalpha.com

Here's Why Viking Therapeutics Bounced Back Today

August 20 at 2:03 PM | fool.com

Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate

August 20 at 1:30 PM | insidermonkey.com

Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study

August 20 at 12:46 PM | zacks.com

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

August 20 at 10:31 AM | zacks.com

Viking Therapeutics: What's Happening With VKTX Stock?

August 20 at 10:03 AM | forbes.com

Viking Therapeutics shares tumble after obesity drug trial disappoints

August 20 at 3:32 AM | proactiveinvestors.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH, VKTX, TGTX, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.74 +0.96 (+3.87%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$25.58 -0.15 (-0.60%)

As of 08/22/2025 07:24 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Amphastar Pharmaceuticals NASDAQ:AMPH

$30.50 +0.84 (+2.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$30.40 -0.11 (-0.34%)

As of 08/22/2025 07:06 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

TG Therapeutics NASDAQ:TGTX

$29.44 +0.67 (+2.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$29.48 +0.04 (+0.15%)

As of 08/22/2025 07:59 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Viking Therapeutics NASDAQ:VKTX

$26.00 +0.34 (+1.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$26.05 +0.05 (+0.21%)

As of 08/22/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time